BioSpace News Archive

IVERIC bio Announces First Patient Dosed in Second Zimura ® Phase 3 Clinical Trial for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration NEW YORK--( BUSINESS WIRE )-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced the first patient has been dosed in GATHER2, also known as ISEE2008, the second Phase 3 clinical trial for Zimura ® (avacincaptad pegol), a novel complement C5 inhibitor, in development for the treatment of ge

Vycor Medical, Inc. announced that its wholly owned subsidiary, NovaVision, Inc., has signed an agreement in principle to enter into an exclusive licensing agreement with HelferApp GmbH.

Advanced data visualization company Zoic Labs has partnered with The Krogan Lab, a world-renowned scientific research unit at Quantitative Biosciences Institute (QBI) at the UC San Francisco, to

Vertex Announces Expansion of Reimbursement Agreement With NHS England to Include KAFTRIO ® (ivacaftor/tezacaftor/elexacaftor) in Combination With KALYDECO ® (ivacaftor) -CF patients in England will be among the first in Europe to benefit from access to KAFTRIO ® , if the medicine is approved by the European Commission- LONDON--( BUSINESS WIRE )-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has expanded its reimburs

The American College of Clinical Pharmacology ® (ACCP) is pleased to announce the 2020 ACCP Annual Meeting (#2020ACCP) is now a virtual meeting to be held September 21 st – 23 rd ! While the vi

Qr8 Health, Inc announced that is has launched two commercial FDA registered products, PST Snapshot™, a rapid digital cognitive function test that measures information processing speed and Cognition Snapshot™, a digital application that combines the PST with a test for visual memory.

Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that Caroline Heinz , co-CEO of its subsidiary HempMeds® , was featured in the major business pu

French/American Contract Services Organisation boosts its offer to CNS/PNS drug development companies

Meissa’s COVID-19 vaccine candidate, MV-014-210, is designed to be delivered as a single, intranasal, adjuvant-free dose, that is economical and can be rapidly scaled to supply global demands Preliminary clinical data show MV-012-968, the company’s vaccine candidate for respiratory syncytial virus, is heavily attenuated and induces a RSV-specific mucosal IgA response in the majority of healthy adult, seropositive recipients SOUTH SAN FRANCIS

IlluminOss Medical , a medical device company focused on minimally invasive orthopedic fracture repair, today announced that it has received expanded U.S. Food and Drug Administra